参考文献
1.NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines): Thyroid Carcinoma Version 1.2019 — March 28, 2019.
2.American Joint Committee on Cancer(AJCC)Cancer Staging System(8th ed., 2017).
3.Siegel RL, Miller KD, Jemal A.Cancer statistics, 2018.CA Cancer J Clin 2018, 68: 7-30.
4.Jonklaas J, Nogueras-Gonzalez G, Munsell M, et al.The impact of age and gender on papillary thyroid cancer survⅣal.J Clin Endocrinol Metab 2012, 97: E878-887.
5.Davies L, Welch HG.Current thyroid cancer trends in the United States.JAMA Otolaryngol Head Neck Surg 2014, 140: 317-322.
6.Bann DV, Goyal N, Camacho F, et al.Increasing incidence of thyroid cancer in the Commonwealth of Pennsylvania.JAMA Otolaryngol Head Neck Surg 2014, 140: 1149-1156.
7.Aschebrook-Kilfoy B, Kaplan EL, Chiu BC, et al.The acceleration in papillary thyroid cancer incidence rates is similar among racial and ethnic groups in the United States.Ann Surg Oncol 2013, 20: 2746-2753.
8.Schneider DF, Elfenbein D, Lloyd RV, et al.Lymph node metastases do not impact survival in follicular variant papillary thyroid cancer.Ann Surg Oncol 2015, 22: 158-163.
9.Wang TS, Goffredo P, Sosa JA, et al.Papillary thyroid microcarcinoma: an over-treated malignancy?World J Surg 2014, 38: 2297-2303.
10.Aschebrook-Kilfoy B, Grogan RH, Ward MH, et al.Follicular thyroid cancer incidence patterns in the United States, 1980-2009.Thyroid 2013, 23: 1015-1021.
11.Schlumberger M, Catargi B, Borget I, et al.Strategies of radioiodine ablation in patients with low-risk thyroid cancer.N Engl J Med 2012, 366: 1663-1673.
12.Pellegriti G, Frasca F, Regalbuto C, et al.Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors.J Cancer Epidemiol 2013, 2013: 965212.(https://www.daowen.com)
13.Rinaldi S, Plummer M, Biessy C, et al.Thyroidstimulating hormone, thyroglobulin, and thyroid hormones and risk of differentiated thyroid carcinoma: the EPIC study.J Natl Cancer Inst 2014, 106: dju097.
14.Cibas ES, Ali SZ.The 2017 Bethesda System for Reporting Thyroid Cytopathology.Thyroid 2017, 27: 1341-1346.
15.Giordano TJ, Beaudenon-Huibregtse S, Shinde R, et al.Molecular testing for oncogenic gene mutations in thyroid lesions: a case-control validation study in 413 postsurgical specimens.Hum Pathol 2014, 45: 1339-1347.
16.Yarchoan M, LiVolsi VA, Brose MS.BRAF mutation and thyroid cancer recurrence.J Clin Oncol 2015, 33: 7-8.
17.Li C, Lee KC, Schneider EB, et al.BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis.J Clin Endocrinol Metab 2012, 97: 4559-4570.
18.Vuong HG, Kondo T, Pham TQ, et al.Prognostic significance of diffuse sclerosing variant papillary thyroid carcinoma: a systematic review and meta-analysis.Eur JEndocrinol 2017, 176: 431-439.
19.Patel KN.Noninvasive Encapsulated Follicular Variant of Papillary Thyroid “Cancer”(or Not): Time for a Name Change.JAMAOncol 2016, 2: 1005-1006.
20.Brito JP, Hay ID, Morris JC.Low risk papillary thyroid cancer.BMJ 2014, 348: g3045.
21.Bales SR, Chopra IJ.Targeted treatment of differentiated and medullary thyroid cancer.J Thyroid Res 2011: 102636.
22.Wells SA Jr., Asa SL, Dralle H, et al.Revised american thyroid association guidelines for the management of medullary thyroid carcinoma.Thyroid 2015, 25: 567-610.
23.Sherman SI.Anaplastic carcinoma: Clinical aspects.In: Wartofsky L, Van Nostrand D, eds.ThyroidCancer: A Comprehensive Guide to Clinical Management, 2nd ed.Totowa, NJ: Humana Press, 2006, 629-632.
24.Savvides P, Nagaiah G, Lavertu P, et al.Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.Thyroid 2013, 23: 600-604.